Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Lineage Cell Therapeutics Inc (LCTX)

Lineage Cell Therapeutics Inc (LCTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 434,538
  • Shares Outstanding, K 162,141
  • Annual Sales, $ 1,830 K
  • Annual Income, $ -20,650 K
  • 60-Month Beta 1.90
  • Price/Sales 244.19
  • Price/Cash Flow N/A
  • Price/Book 3.72
Trade LCTX with:

Options Overview

Details
  • Implied Volatility 102.59%
  • Historical Volatility 34.76%
  • IV Percentile 20%
  • IV Rank 3.51%
  • IV High 818.44% on 09/03/20
  • IV Low 76.55% on 05/24/21
  • Put/Call Vol Ratio 0.90
  • Today's Volume 211
  • Volume Avg (30-Day) 385
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 16,339
  • Open Int (30-Day) 16,002

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.03
  • Number of Estimates 2
  • High Estimate -0.03
  • Low Estimate -0.03
  • Prior Year -0.04
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.45 +8.57%
on 07/19/21
3.00 -11.33%
on 06/25/21
-0.13 (-4.66%)
since 06/23/21
3-Month
2.14 +24.30%
on 05/13/21
3.00 -11.33%
on 06/25/21
+0.19 (+7.69%)
since 04/23/21
52-Week
0.79 +238.85%
on 07/29/20
3.13 -15.06%
on 02/17/21
+1.84 (+225.78%)
since 07/23/20

Most Recent Stories

More News
Thinking about buying stock in AMC, Corbus Pharmaceuticals, Syros Pharmaceuticals, Canaan, or Lineage Cell Therapeutics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, CRBP, SYRS, CAN, and LCTX.

LCTX : 2.66 (-0.75%)
CAN : 5.76 (-6.80%)
CRBP : 1.4100 (-3.42%)
SYRS : 4.69 (-6.39%)
AMC : 36.99 (-0.67%)
Lineage Cell (LCTX) Reports Q1 Loss, Misses Revenue Estimates

Lineage Cell (LCTX) delivered earnings and revenue surprises of -50.00% and -63.46%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

LCTX : 2.66 (-0.75%)
Thinking about buying stock in Microvision, Lineage Cell Therapeutics, vTv Therapeutics, electroCore, or Arcadia Biosciences?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MVIS, LCTX, VTVT, ECOR, and RKDA.

LCTX : 2.66 (-0.75%)
ECOR : 1.0100 (-0.98%)
MVIS : 13.80 (-2.68%)
VTVT : 2.02 (-2.42%)
RKDA : 2.38 (-0.42%)
Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer Immunotherapy

Immunomic Therapeutics, Inc., ("ITI"), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today a worldwide license and development...

LCTX : 2.66 (-0.75%)
Thinking about buying stock in Arcadia Biosciences, Ocugen, Broadwind, Surface Oncology, or Lineage Cell Therapeutics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RKDA, OCGN, BWEN, SURF, and LCTX.

LCTX : 2.66 (-0.75%)
OCGN : 6.94 (-1.98%)
SURF : 6.04 (-5.33%)
BWEN : 4.00 (-3.38%)
RKDA : 2.38 (-0.42%)
Lineage to Present at the Benzinga Global Biotech Small Cap Conference on March 24, 2021

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley,...

LCTX : 2.66 (-0.75%)
Lineage Cell (LCTX) Tops Q4 Earnings Estimates

Lineage Cell (LCTX) delivered earnings and revenue surprises of 120.00% and -73.57%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

LCTX : 2.66 (-0.75%)
Lineage Cell Therapeutics Raises $35.9 Million From Sales of Marketable Securities Holdings and an At-the-Market Equity Offering

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that it raised $11 million...

LCTX : 2.66 (-0.75%)
OCX : 5.40 (-1.28%)
HDST : 0.0100 (unch)
AGE : 1.5000 (-1.96%)
Analysts Estimate Lineage Cell (LCTX) to Report a Decline in Earnings: What to Look Out for

Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LCTX : 2.66 (-0.75%)
Thinking about buying stock in Dare Bioscience, Endra Life Sciences, Lineage Cell Therapeutics, Inuvo Inc, or eMagin Corp?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DARE, NDRA, LCTX, INUV, and EMAN.

EMAN : 2.95 (+2.43%)
INUV : 0.8115 (-6.30%)
LCTX : 2.66 (-0.75%)
DARE : 1.4900 (+0.68%)
NDRA : 1.8500 (-5.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are...

See More

Key Turning Points

3rd Resistance Point 2.79
2nd Resistance Point 2.75
1st Resistance Point 2.71
Last Price 2.66
1st Support Level 2.62
2nd Support Level 2.58
3rd Support Level 2.54

See More

52-Week High 3.13
Last Price 2.66
Fibonacci 61.8% 2.24
Fibonacci 50% 1.96
Fibonacci 38.2% 1.68
52-Week Low 0.79

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar